A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.

Miller, K D; Gradishar, W; Schuchter, L; Sparano, J A; Cobleigh, M; Robert, N; Rasmussen, H; Sledge, G W

Miller, K D; Gradishar, W; Schuchter, L; Sparano, J A; Cobleigh, M; Robert, N; Rasmussen, H; Sledge, G W.

Affiliation

Miller KD; Indiana University, Indianapolis, IN, USA. kathmill@iupui.edu

Ann Oncol ; 13(8): 1220-4, 2002 Aug.

Article in En | MEDLINE | ID: mdl-12181245

Subject(s)

Breast Neoplasms/metabolism; Enzyme Inhibitors/pharmacokinetics; Hydroxamic Acids/pharmacokinetics; Adult; Aged; Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Chemotherapy, Adjuvant; Enzyme Inhibitors/adverse effects; Enzyme Inhibitors/therapeutic use; Female; Humans; Hydroxamic Acids/adverse effects; Hydroxamic Acids/therapeutic use; Matrix Metalloproteinase Inhibitors; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Safety; Survival Rate; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Enzyme Inhibitors / Hydroxamic Acids Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2002 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links